Collectively, these studies illustrate a key pro-tumorigenic role for CD200 in directly suppressing T-cell and NK cell anti-tumor function and that blocking the engagement of the CD200-CD200R axis may provide therapeutic benefit to patients with CD200-expressing tumors. The gene discussed is CD200R1; the disease is neoplasm.